Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback